| Literature DB >> 27389143 |
William DeCoteau1, Karin L Heckman2, Ana Y Estevez3, Kenneth J Reed4, Wendi Costanzo4, David Sandford4, Paige Studlack1, Jennifer Clauss2, Elizabeth Nichols2, Jennifer Lipps2, Matthew Parker2, Bonnie Hays-Erlichman2, J C Leiter5, Joseph S Erlichman2.
Abstract
Cerium oxide nanoparticles (CeNPs) neutralize reactive oxygen and nitrogen species. Since oxidative stress plays a role in amyotrophic lateral sclerosis (ALS) in humans and in the SOD1G93A mouse model of ALS, we tested whether administration of CeNPs would improve survival and reduce disease severity in SOD1G93A transgenic mice. Twice a week intravenous treatment of SOD1G93A mice with CeNPs started at the onset of muscle weakness preserved muscle function and increased longevity in males and females. Median survival after the onset of CeNP treatment was 33.0±3.7days (N=20), and only 22.0±2.5days in mice treated with vehicle, control injections (N=27; P=0.022). Since these citrate-EDTA stabilized CeNPs exhibited catalase and oxidase activity in cell-free systems and in in vitro models of ischemic oxidative stress, we hypothesize that antioxidant activity is the protective mechanism prolonging survival in the SOD1G93A mice.Entities:
Keywords: Amyotrophic lateral sclerosis; Cerium oxide nanoparticles; Oxidative stress
Mesh:
Substances:
Year: 2016 PMID: 27389143 DOI: 10.1016/j.nano.2016.06.009
Source DB: PubMed Journal: Nanomedicine ISSN: 1549-9634 Impact factor: 5.307